Ascendiant lowered the firm’s price target on Outlook Therapeutics (OTLK) to $6 from $10 and keeps a Buy rating on the shares following the Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
- Outlook Therapeutics advances FDA dialogue on ONS-5010 approval
- Outlook Therapeutics provides update following FDA meeting on ONS-5010
- Outlook enters distribution agreement for sale of Lytenava in Switzerland
- Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance